Lupin launches dementia drug in US
New Delhi: Drug firm Lupin said it has launched its Memantine Hydrochloride extended-release capsules in the American market after getting approval from the US health regulator.
The company has launched Memantine Hydrochloride extended-release capsules in the strengths of 7mg, 14mg, 21mg, 28mg having received an approval from the United States Food and Drug Administration (USFDA) earlier, Lupin said in a statement.
The company's products are generic versions of Allergan's Namenda XR capsules, it added.
"It is indicated for the treatment of moderate to severe dementia of the Alzheimer's type," Lupin said.
As per IQVIA MAT December 2017 data, Memantine Hydrochloride ER capsules 7mg, 14mg, 21mg, 28mg had annual sales of approximately USD 936 million in the US, it added.
AllerganAlzheimer'sAmerican marketdementiadementia druglaunchesLupinMemantine HydrochlorideMemantine Hydrochloride extended-release capsulesNamenda XR Capsulessevere dementiaUnited States Food and Drug AdministrationUSUSFDA
Source : PTINext Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd